Stockwatch: Beware The Biotech Folly Of Self-Commercialization
Partnering A First Asset to Big Pharma Brings More Benefits Than Money
If the lengthy litigation history is any guide, Amgen regretted licensing its first product to a big pharma partner, probably because the product was so successful. For most first products, however, a big pharmaceutical collaboration can bring many benefits but the converse – self-commercialization of the first product – has far fewer positive historical connotations.
